LTSE-2578
Pulmonary Arterial Hypertension
Key Facts
About Structure Therapeutics
Structure Therapeutics is on a mission to develop best-in-class oral small molecule therapeutics for validated but challenging G protein-coupled receptor (GPCR) targets, primarily in large markets like obesity and diabetes. Since its 2016 founding, the company has rapidly advanced a promising pipeline, most notably its GLP-1 receptor agonist GSBR-1290, and achieved a successful public listing, reflecting strong investor confidence in its differentiated structural biology platform. Its strategy hinges on using atomic-level insights to design superior oral drugs that could capture significant market share from incumbent injectable therapies.
View full company profileTherapeutic Areas
Other Pulmonary Arterial Hypertension Drugs
| Drug | Company | Phase |
|---|---|---|
| Tadliq® (Tadalafil Oral Suspension) | CMP Pharma | Approved |
| JTV-161 | Akros Pharma | Phase1 |
| PROPHET | Occlutech | Pilot |
| Soft Mist Inhaler for PAH (with unnamed Pharma Partner) | Resyca | Not Disclosed |
| Tyvaso DPI® | MannKind Corp | Approved |
| F230 | Gyre Therapeutics | Not Specified |